WO2013166281A8 - Bi-functional compositions for targeting cells to diseased tissues and methods of using same - Google Patents

Bi-functional compositions for targeting cells to diseased tissues and methods of using same Download PDF

Info

Publication number
WO2013166281A8
WO2013166281A8 PCT/US2013/039255 US2013039255W WO2013166281A8 WO 2013166281 A8 WO2013166281 A8 WO 2013166281A8 US 2013039255 W US2013039255 W US 2013039255W WO 2013166281 A8 WO2013166281 A8 WO 2013166281A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
target tissue
disclosed
same
compositions
Prior art date
Application number
PCT/US2013/039255
Other languages
French (fr)
Other versions
WO2013166281A1 (en
Inventor
Eduardo MARBÁN
Ke CHANG
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Publication of WO2013166281A1 publication Critical patent/WO2013166281A1/en
Publication of WO2013166281A8 publication Critical patent/WO2013166281A8/en
Priority to US14/333,440 priority Critical patent/US20150010640A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Disclosed herein are compositions and methods for the targeted delivery of therapeutic cells to a target tissue, in several embodiments, the therapeutic cells are captured by an antibody that is coupled to a magnetic particle, which is in turn coupled to an antibody directed against a specific marker expressed by a target tissue. In some embodiments, the target tissue is damaged or diseased cardiac tissue, in several embodiments, in conjunction with an applied magnetic field, the methods and compositions disclosed herein yield enhanced delivery of the therapeutic cells to the target tissue, thereby resulting in repair and/or regeneration of the target tissue. Also disclosed are methods for the non-invasive detection of immune responses to transplanted cells or organs.
PCT/US2013/039255 2009-10-27 2013-05-02 Bi-functional compositions for targeting cells to diseased tissues and methods of using same WO2013166281A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/333,440 US20150010640A1 (en) 2009-10-27 2014-07-16 Bi-functional compositions for targeting cells to diseased tissues and methods of using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261641784P 2012-05-02 2012-05-02
US61/641,784 2012-05-02

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US13/504,747 Continuation-In-Part US20120253102A1 (en) 2009-10-27 2010-10-27 External magnetic force for targeted cell delivery with enhanced cell retention
PCT/US2010/054358 Continuation-In-Part WO2011056685A1 (en) 2009-10-27 2010-10-27 External magnetic force for targeted cell delivery with enhanced cell retention

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/333,440 Continuation US20150010640A1 (en) 2009-10-27 2014-07-16 Bi-functional compositions for targeting cells to diseased tissues and methods of using same

Publications (2)

Publication Number Publication Date
WO2013166281A1 WO2013166281A1 (en) 2013-11-07
WO2013166281A8 true WO2013166281A8 (en) 2013-12-27

Family

ID=49514885

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/039255 WO2013166281A1 (en) 2009-10-27 2013-05-02 Bi-functional compositions for targeting cells to diseased tissues and methods of using same

Country Status (1)

Country Link
WO (1) WO2013166281A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016029558A2 (en) * 2014-06-17 2017-08-22 Igenomix S L stem cell therapy in endometrial pathologies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702905A (en) * 1994-09-28 1997-12-30 Spectral Diagnostics Monoclonal antibody to human ventricular myosin light chains
EP2287315A1 (en) * 2003-03-04 2011-02-23 Intercell AG Streptococcus pyogenes antigens
JP5053089B2 (en) * 2004-08-03 2012-10-17 ベクトン・ディキンソン・アンド・カンパニー Use of magnetic materials for direct isolation of compounds and fractionation of multicomponent samples
WO2011056685A1 (en) * 2009-10-27 2011-05-12 Cedars-Sinai Medical Center External magnetic force for targeted cell delivery with enhanced cell retention

Also Published As

Publication number Publication date
WO2013166281A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
WO2011106788A3 (en) Car peptide for homing, diagnosis, & targeted therapy for pulmonary and fibrotic disorders
WO2013040078A3 (en) Engineered tissues for in vitro research uses, arrays thereof, and methods of making the same
WO2009100137A3 (en) Magnetic cells for localizing delivery and tissue repair
NZ612320A (en) Materials and methods for conjugating a water soluble fatty acid derivative to a protein
WO2013089882A3 (en) Recurrent gene fusions in breast cancer
WO2014183066A3 (en) Protein modification of living cells using sortase
EA201390642A1 (en) CYTOTOXIC AGENTS CONTAINING NEW DERIVATIVES OF ANZAMITOCINE
WO2016084081A3 (en) Devices and methods for pulmonary hypertension treatment
EP3238782A3 (en) Methods of treating cancer
WO2014028493A3 (en) Exosomes and micro-ribonucleic acids for tissue regeneration
NZ730563A (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
WO2011135458A3 (en) Efficient ultrasound focusing
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
WO2013014538A3 (en) Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
WO2012009406A3 (en) Gold particles and methods of making and using the same in cancer treatment
MX2015003643A (en) Method of treating cancer.
WO2013063419A3 (en) A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
IN2014DN09902A (en)
WO2008116157A3 (en) Mesenchymal stem cells and uses therefor
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
WO2011034906A3 (en) Recurrent gene fusions in prostate cancer
AU335450S (en) Animal trap
WO2012135562A3 (en) Polymer conjugates targeting cells and methods related thereto

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13784671

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13784671

Country of ref document: EP

Kind code of ref document: A1